Core Viewpoint - Polyrizon Ltd., a pre-clinical-stage biotechnology company, has filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2025, with the U.S. Securities and Exchange Commission [1] Company Overview - Polyrizon specializes in developing innovative medical device hydrogels delivered as nasal sprays, which create a hydrogel-based shield in the nasal cavity to protect against viruses and allergens [3] - The company's proprietary technology, Capture and Contain TM (C&C), utilizes naturally occurring building blocks to form a barrier in the nasal cavity, potentially acting as a "biological mask" [3] - Polyrizon is also developing its Trap and Target ™ (T&T) technology, focused on the nasal delivery of active pharmaceutical ingredients (APIs), which is currently in an earlier stage of pre-clinical development [3] Report Availability - The Annual Report on Form 20-F is accessible on the SEC's website and Polyrizon's Investor Relations website, with shareholders able to request copies free of charge [2]
Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025